AI assistant
Q32 Bio Inc. — Director's Dealing 2021
Jan 8, 2021
34891_dirs_2021-01-08_83828fea-a5d1-492c-a0ce-0c07b7c4d063.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Homology Medicines, Inc. (FIXX)
CIK: 0001661998
Period of Report: 2021-01-06
Reporting Person: Seymour Albert (Chief Scientific Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-01-06 | Common Stock | S | 9897 | $12.0638 | Disposed | 134120 | Direct |
| 2021-01-07 | Common Stock | S | 5103 | $12.0457 | Disposed | 129017 | Direct |
Footnotes
F1: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 3, 2020.
F2: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $12.00 to $12.21. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $12.00 to $12.17. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.